samedan logo
 
 
 
spacer
home > ebr > spring 2004 > new trends in dermatology clinical research
PUBLICATIONS
European Biopharmaceutical Review

New Trends in Dermatology Clinical Research

In dermatology it is often possible to establish clinical efficacy before committing to a full clinical and safety programme. This is because the focus of dermatology - the skin - is directly accessible for therapy. In contrast to systemic or topical application to large areas, in many cases a very small treatment area can be selected for dosing of topical therapies, effectively eliminating risks associated with systemic exposure.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Betsy Hughes-Formella, Managing Director at Bioskin GmbH

Dr Betsy Hughes-Formella received her PhD in Physiology from the University of Georgia in Athens, Georgia in 1983. She moved to Germany to join a research team at the University Medical Center in Hamburg. Her research interests were in the area of steroid receptors in the neuromuscular system and later in the pathogenesis of melanoma. In 1992 Dr Hughes joined Bioskin GmbH as Managing Director. In her current capacity she consultants and advises on clinical development concepts and study designs for Bioskin sponsors. In addition, she is responsible for the co-ordination of the company's business development and strategic alliance opportunities. She is an active member of several scientific societies, including a position on the board of regents of the German Association of Applied Human Pharmacology (AGAH) and the working group for dermocosmetics in the German Association for Dermopharmacie (GD).

spacer
Dr Betsy Hughes-Formella
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CARMAT Announces the First Human Implant of its Total Artificial Heart in the United States

Paris, July 15, 2021 - 7 am CEST CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the first implantation of its bioprosthetic artificial heart, Aeson®, in the United States within the framework of the Early Feasibility Study (EFS).
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement